DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $12.3333.

Several brokerages have weighed in on DMAC. Wall Street Zen raised DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Monday, April 20th.

DiaMedica Therapeutics Stock Up 0.4%

NASDAQ DMAC traded up $0.03 during trading hours on Tuesday, reaching $8.04. 79,426 shares of the company were exchanged, compared to its average volume of 208,326. The stock has a market capitalization of $433.41 million, a P/E ratio of -11.38 and a beta of 0.97. DiaMedica Therapeutics has a 1 year low of $3.58 and a 1 year high of $10.42. The business’s 50 day simple moving average is $6.16 and its 200-day simple moving average is $7.16.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). As a group, sell-side analysts anticipate that DiaMedica Therapeutics will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its holdings in DiaMedica Therapeutics by 62.5% during the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock worth $290,000 after purchasing an additional 16,446 shares in the last quarter. Renaissance Technologies LLC purchased a new position in DiaMedica Therapeutics during the 1st quarter valued at about $356,000. Sei Investments Co. increased its position in shares of DiaMedica Therapeutics by 100.0% during the first quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock valued at $754,000 after buying an additional 55,660 shares during the period. World Investment Advisors increased its position in shares of DiaMedica Therapeutics by 7.7% during the fourth quarter. World Investment Advisors now owns 36,975 shares of the company’s stock valued at $294,000 after buying an additional 2,650 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of DiaMedica Therapeutics by 29.9% in the fourth quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock worth $148,000 after buying an additional 4,293 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical?stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein?kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.